Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)

Market Cap	15.96B
Revenue (ttm)	2.85B
Net Income (ttm)	170.02M
Shares Out	1.12B
EPS (ttm)	0.15
PE Ratio	95.01
Forward PE	50.09
Dividend	0.09 (0.63%)
Ex-Dividend Date	Jun 6, 2025

Volume	10,032,177
Average Volume	10,181,866
Open	13.98
Previous Close	14.34
Day's Range	13.98 - 14.45
52-Week Range	12.93 - 23.45
Beta	1.13
RSI	52.46
Earnings Date	Aug 21, 2025

About SHE:300601

Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. Its marketed vaccines include SARS-COV-2 vaccines, HIB conjugate vaccines, 13-valent pneumococcal conjugate vaccines, recombinant hepatitis B vaccines, 23-valent pneumococcal polysaccharide vaccines, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccines, cell-free whitebait b-type haemophilus influenzae combined vaccines, and measles and rubella combined vaccines. The company’...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,913
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300601

Financial Performance

In 2024, SHE:300601's revenue was 2.65 billion, a decrease of -23.75% compared to the previous year's 3.48 billion. Earnings were 201.65 million, a decrease of -76.59%.